0001209191-20-019430.txt : 20200316 0001209191-20-019430.hdr.sgml : 20200316 20200316213950 ACCESSION NUMBER: 0001209191-20-019430 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200316 FILED AS OF DATE: 20200316 DATE AS OF CHANGE: 20200316 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ho Robert CENTRAL INDEX KEY: 0001806254 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36327 FILM NUMBER: 20719098 MAIL ADDRESS: STREET 1: 360-1616 EASTLAKE AVENUE EAST CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Neoleukin Therapeutics, Inc. CENTRAL INDEX KEY: 0001404644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: SUITE 360 - 1616 EASTLAKE AVE EAST CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-732-2133 MAIL ADDRESS: STREET 1: SUITE 360 - 1616 EASTLAKE AVE EAST CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS, INC DATE OF NAME CHANGE: 20140128 FORMER COMPANY: FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS (USA) INC DATE OF NAME CHANGE: 20070626 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-03-16 0 0001404644 Neoleukin Therapeutics, Inc. NLTX 0001806254 Ho Robert C/O NEOLEUKIN THERAPEUTICS, INC. 360-1616 EASTLAKE AVENUE E. SEATTLE WA 98102 0 1 0 0 Chief Financial Officer Restricted Stock Units 0.00 2020-03-16 4 A 0 75000 0.00 A Common Stock 75000 75000 D Stock Option (Right to Buy) 6.44 2020-03-16 4 A 0 200000 0.00 A 2030-03-16 Common Stock 200000 200000 D Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. The RSUs will vest as to 1/3 of the total number of shares underlying the award on each of March 16, 2021, March 16, 2022 and March 16, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date. The option vests as to 1/4 of the total shares on March 16, 2021, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date. /s/ Kris McGrew, as Attorney-in-Fact for Robert Ho 2020-03-16